TITLE

The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis

AUTHOR(S)
Henry, David; Carless, Paul; Fergusson, Dean; Laupacis, Andreas
PUB. DATE
January 2009
SOURCE
CMAJ: Canadian Medical Association Journal;1/20/2009, Vol. 180 Issue 2, p183
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Because of recent concerns about the safety of aprotinin, we updated our 2007 Cochrane review that compared the relative benefits and risks of aprotinin and the lysine analogues tranexamic acid and epsilon aminocaproic acid. Methods: We searched electronic databases, including CENTRAL, MEDLINE, EMBASE, Google and Google Scholar for trials of antifibrinolytic drugs used in adults scheduled for cardiac surgery. Searches were updated to January 2008. By comparing aprotinin and the 2 lysine analogues to control, we derived indirect head-to-head comparisons of aprotinin to the other drugs. We derived direct estimates of risks and benefits by pooling estimates from head-to-head trials of aprotinin and tranexamic acid or epsilon aminocaproic acid. Results: For indirect estimates, we identified 49 trials involving 182 deaths among 7439 participants. The summary relative risk (RR) for death with aprotinin versus placebo was 0.93 (95% confidence interval [CI] 0.69-1.25). In the 19 trials that included tranexamic acid, there were 24 deaths among 1802 participants. The summary RR was 0.55 (95% CI 0.24-1.25). From the risk estimates derived for individual drugs, we calculated an indirect summary RR of death with use of aprotinin versus tranexamic acid of 1.69 (95% CI 0.70-4.10). To calculate direct estimates of death for aprotinin versus tranexamic acid, we identified 13 trials with 107 deaths among 3537 participants. The summary RR was 1.43 (95% CI 0.98-2.08). Among the 1840 participants, the calculated estimates of death for aprotinin compared directly to epsilon aminocaproic acid was 1.49 (95% CI 0.98-2.28). We found no evidence of an increased risk of myocardial infarction with use of aprotinin compared with the lysine analogues in either direct or indirect analyses. Compared with placebo or no treatment, all 3 drugs were effective in reducing the need for red blood cell transfusion. The RR of transfusion with use of aprotinin was 0.66 (95% CI 0.61-0.72). The RR of transfusion was 0.70 (95% CI 0.61-0.80) for tranexamic acid, and it was 0.75 (95% CI 0.58-0.96) for use of epsilon aminocaproic acid. Aprotinin was also effective in reducing the need for reoperation because of bleeding (RR 0.48, 95% CI 0.34-0.67). Interpretation: The risk of death tended to be consistently higher with use of aprotinin than with use of lysine analogues. Aprotinin had no clear advantages to offset these harms. Either tranexamic acid or epsilon aminocaproic acid should be recommended to prevent bleeding after cardiac surgery.
ACCESSION #
36087592

 

Related Articles

  • Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial Later, Alexander F.L.; Maas, Jacinta J.; Engbers, Frank H.M.; Versteegh, Michel I.M.; Bruggemans, Eline F.; Dion, Robert A.E.; Klautz, Robert J.M. // European Journal of Cardio-Thoracic Surgery;Aug2009, Vol. 36 Issue 2, p322 

    Abstract: Objective: Tranexamic acid has been suggested to be as effective as aprotinin in reducing blood loss and transfusion requirements after cardiac surgery. Previous studies directly comparing both antifibrinolytics focus on high-risk cardiac surgery patients only or suffer from...

  • Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study Baric, Davor; Biocina, Bojan; Unic, Daniel; Sutlic, Zeljko; Rudez, Igor; Vrca, Vesna Bacic; Brkic, Kristina; Ivkovic, Mira // European Journal of Cardio-Thoracic Surgery;Mar2007, Vol. 31 Issue 3, p366 

    Abstract: Objective: Postoperative bleeding is still one of the most common complications of cardiac surgery. Antifibrinolytic agents successfully reduce bleeding, but there are controversies concerning adverse effects after their systemic use. By topical application of antifibrinolytic agents...

  • Retraction Note to: Correlations of SELE and SELP genetic polymorphisms with myocardial infarction risk: a meta-analysis and meta-regression. Zhao, Yu-Juan; Yang, Xia; Ren, Li; Cai, An-Sheng; Zhang, Yan-Fen // Molecular Biology Reports;Oct2015, Vol. 42 Issue 10, p1461 

    A retraction of the article "Correlations of SELE and SELP genetic polymorphisms with myocardial infarction risk: a meta-analysis and meta-regression" that was published in the 2014 issue is presented.

  • Transfusions in Critically Ill Patients. Ely, E. Wesley; Bernard, Gordon R. // New England Journal of Medicine;02/11/99, Vol. 340 Issue 6, p467 

    Editorial. Presents findings in a study done by the Canadian Critical Care Trials Group, which evaluated red-cell transfusion practices in intensive care units. Statistics on the patients who participated in the study; Findings of high in-hospital mortality rates associated with liberal...

  • Fibrinolýza v kardiochirurgii v postaprotinínovej ére. Ján, Špegár; Petra, Pazderková; Tomáš, Vaněk // Anaesthesiology & Intensive Medicine / Anesteziologie a Intenziv;Oct2011, Vol. 22 Issue 5, p260 

    The use of antifibrinolytics for prevention of massive haemorrhagic events and deterioration during the perioperative course of a patient is a routine practice in many cardiac centres nowadays. Following the with - drawal of the most powerful antifibrinolytic agent aprotinin, attention of the...

  • Safety of antifibrinolytic therapy during cardiac surgery and randomized controlled trials. Koster, A.; Zittermann, A.; Schirmer, U. // BJA: The British Journal of Anaesthesia;Jun2013, Vol. 110 Issue 6, p1055 

    No abstract available.

  • Tranexamic acid: an alternative to aprotinin as antifibrinolytic therapy in pediatric congenital heart surgery Schindler, Ehrenfried; Photiadis, Joachim; Sinzobahamvya, Nicodème; Döres, Albert; Asfour, Boulos; Hraska, Victor // European Journal of Cardio-Thoracic Surgery;Apr2011, Vol. 39 Issue 4, p495 

    Abstract: Objective: There has been concern about the usage of aprotinin, an antifibrinolytic drug that was often used in pediatric cardiac surgery until 2006. At our center, these concerns led to the replacement of aprotinin with tranexamic acid for antifibrinolytic treatment. Methods: In this...

  • Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Grassin-Delyle, S.; Tremey, B.; Abe, E.; Fischler, M.; Alvarez, J. C.; Devillier, P.; Urien, S. // BJA: The British Journal of Anaesthesia;Dec2013, Vol. 111 Issue 6, p916 

    Background Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either low- or...

  • Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction. Marasco, Silvana F.; Pilcher, David; Oto, Takahiro; Chang, Wenly; Griffiths, Anne; Pellegrino, Vince; Chan, Justin; Bailey, Michael // European Journal of Cardio-Thoracic Surgery;Feb2010, Vol. 37 Issue 2, p420 

    Abstract: Objective: Aprotinin has been widely used to reduce bleeding and transfusion requirements in cardiac surgery and in lung transplantation. A recent study found a significant reduction in severe (grade III) primary graft dysfunction (PGD) in lung transplantation where aprotinin had been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics